Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01104532 · ClinicalTrials.gov registry record · Phase 1
A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01104532 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 64 participants.
The verdict
NCT01104532, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate pharmacokinetics, pharmacodynamics and safety following the administration of ASP1941 and sitagliptin in single and multiple doses.
Interventions
- DRUG sitagliptin
- DRUG ASP1941
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2010-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01104532
The ClinicalTrials.gov registry entry for NCT01104532 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sitagliptin is the first listed.
NCT01104532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01104532 about?
NCT01104532 is a clinical study titled "A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Sitagliptin When Given Together to Healthy Subjects". The purpose of the study is to evaluate pharmacokinetics, pharmacodynamics and safety following the administration of ASP1941 and sitagliptin in single and multiple doses.
What is the current status of trial NCT01104532?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2010-02. Estimated completion is 2010-03.
What interventions are being tested in trial NCT01104532?
The interventions under investigation include: sitagliptin (DRUG), ASP1941 (DRUG).
Who is sponsoring clinical trial NCT01104532?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.